Answers are grounded in this paper and cite their sources.
Background: Cytology categories Bethesda III and Bethesda IV thyroid nodules present a diagnostic challenge for both clinicians and patients owing to their heterogeneity and variable risk of malignancy (ROM). According to the Bethesda System, the estimated malignancy risk for these categories is 13%–30% and 23%–34%, respectively. However, institutional variations may exist. This study aimed to determine the ROM specific to our institution and to identify clinical factors associated with malignant outcomes. Methodology: This retrospective study included patients with Bethesda III and IV cytology who underwent thyroidectomy at a tertiary cancer center in Kerala between 2018 and 2022. Demographic, clinical, radiological, and histopathological data were analyzed. Statistical analyses were performed using Chi-square, Mann–Whitney U , and logistic regression tests, with P < 0.05 considered statistically significant. Results: A total of 140 patients were included, the majority being females below 55 years of age. In the Bethesda III category, firm nodule consistency was significantly associated with malignancy ( P = 0.009). In the Bethesda IV group, nodule size, consistency, and TIRADS category showed significant correlations with malignancy. The overall malignancy rates were 72% for Bethesda III (18/25 cases) and 57% for Bethesda IV (66/115 cases), both higher than the standard Bethesda estimates. Conclusion: The malignancy rates for Bethesda III and IV nodules in our cohort were notably higher than those reported in the Bethesda system, emphasizing the need for institution-specific risk assessment. Firm to hard nodule consistency was strongly associated with malignancy, underscoring its value in clinical evaluation.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: